-
EP2564188
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2564188
| EP2564188 - ASSAYS FOR ANTI-DRUG ANTIBODIES IN THE PRESENCE OF ABUNDANT ENDOGENOUS PROTEIN COUNTERPART OF THE DRUG [Right-click to bookmark this link] | Status | The application has been refused Status updated on 04.03.2016 Database last updated on 03.09.2024 | Most recent event Tooltip | 04.03.2016 | Refusal of application | published on 06.04.2016 [2016/14] | Applicant(s) | For all designated states Merrimack Pharmaceuticals, Inc. One Kendall Square Bldg. 700, 2nd Floor Cambridge, MA 02139 / US | [2013/10] | Inventor(s) | 01 /
SONG, Sam Shenghua 22 High Street Walpole, Massachusetts 02081 / US | 02 /
KUDLA, Arthur J. 1 Powder Mill Square Unit 308 Andover, Massachusetts 01810 / US | 03 /
MOODY, Mark David 51 Revolutionary Rd. Concord, Massachusetts 01742 / US | [2013/10] | Representative(s) | Delorme, Nicolas Cabinet Germain & Maureau BP 6153 69466 Lyon Cedex 06 / FR | [2013/10] | Application number, filing date | 11777907.4 | 26.04.2011 | WO2011US33916 | Priority number, date | US20100327906P | 26.04.2010 Original published format: US 327906 P | [2013/10] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2011139681 | Date: | 10.11.2011 | Language: | EN | [2011/45] | Type: | A1 Application with search report | No.: | EP2564188 | Date: | 06.03.2013 | Language: | EN | The application published by WIPO in one of the EPO official languages on 10.11.2011 takes the place of the publication of the European patent application. | [2013/10] | Search report(s) | International search report - published on: | US | 10.11.2011 | (Supplementary) European search report - dispatched on: | EP | 26.08.2013 | Classification | IPC: | G01N33/00 | [2013/10] | CPC: |
G01N33/6854 (EP,US);
G01N2333/765 (EP,US)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2013/10] | Title | German: | ASSAYS FÜR ANTIKÖRPER GEGEN BIOWIRKSTOFFE UNTER VERWENDUNG ABUNDANTER ENDOGENER PROTEIN-ANTAGONISTEN DIESES WIRKSTOFFS | [2013/10] | English: | ASSAYS FOR ANTI-DRUG ANTIBODIES IN THE PRESENCE OF ABUNDANT ENDOGENOUS PROTEIN COUNTERPART OF THE DRUG | [2013/10] | French: | ESSAIS POUR DES ANTICORPS ANTI-MÉDICAMENTS EN PRÉSENCE D'HOMOLOGUES PROTÉIQUE ENDOGÈNES ABONDANTS DU MÉDICAMENT | [2013/10] | Entry into regional phase | 25.10.2012 | National basic fee paid | 25.10.2012 | Search fee paid | 25.10.2012 | Designation fee(s) paid | 25.10.2012 | Examination fee paid | Examination procedure | 25.10.2012 | Examination requested [2013/10] | 23.07.2013 | Despatch of communication of loss of particular rights: Claims {1} | 11.03.2014 | Amendment by applicant (claims and/or description) | 21.05.2014 | Despatch of a communication from the examining division (Time limit: M06) | 12.11.2014 | Reply to a communication from the examining division | 14.10.2015 | Despatch of a communication from the examining division (Time limit: M04) | 19.10.2015 | Reply to a communication from the examining division | 19.11.2015 | Despatch of communication that the application is refused, reason: substantive examination [2016/14] | 29.11.2015 | Application refused, date of legal effect [2016/14] | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 21.05.2014 | Request for further processing for: | Loss of rights: Claims | 01.08.2013 | Request for further processing filed | 01.08.2013 | Full payment received (date of receipt of payment) Request granted | 13.08.2013 | Decision despatched | Fees paid | Renewal fee | 29.04.2013 | Renewal fee patent year 03 | 28.04.2014 | Renewal fee patent year 04 | 27.04.2015 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [X]US2008009446 (YU ZAILIN [US], et al) [X] 13 * examples *; | [I] - BOURDAGE ET AL, "An Affinity Capture Elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, (20070925), vol. 327, no. 1-2, doi:10.1016/J.JIM.2007.07.004, ISSN 0022-1759, pages 10 - 17, XP022266386 [I] 1-16 * the whole document * DOI: http://dx.doi.org/10.1016/j.jim.2007.07.004 | [I] - SMITH ET AL, "Detection of antibodies against therapeutic proteins in the presence of residual therapeutic protein using a solid-phase extraction with acid dissociation (SPEAD) sample treatment prior to ELISA", REGULATORY TOXICOLOGY AND PHARMACOLOGY, ACADEMIC PRESS,NEW YORK, NY, US, (20071113), vol. 49, no. 3, doi:10.1016/J.YRTPH.2007.07.005, ISSN 0273-2300, pages 230 - 237, XP022343220 [I] 1-16 * abstract * DOI: http://dx.doi.org/10.1016/j.yrtph.2007.07.005 | [I] - R C GUPTA ET AL, "Isolation of circulating immune complexes by conglutinin and separation of antigen from dissociated complexes by immobilized protein A", CLIN. EXP. IMMUNOL., (19811001), vol. 46, pages 9 - 19, XP055075457 [I] 1-16 * abstract * * p17 third par * * par 2.5 and 2.6 * | International search | [Y]US2008009446 (YU ET AL.); | [Y]US2007202505 (CHENCHIK) | [Y] - BOURDAGE ET AL., "An affinity capture elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug.", JOURNAL OF IMMUNOLOGICAL METHODS, (2007), vol. 327, pages 10 - 17, XP022266386 DOI: http://dx.doi.org/10.1016/j.jim.2007.07.004 | [Y] - FELDMAN ET AL., "Treatment of relapsed or refractory acute myeloid leukemia with humanized anti- CD33 monoclonal antibody HuM195.", LEUKEMIA, (2003), vol. 17, pages 314 - 318, XP009142408 |